Effect of alogliptin and pioglitazone combination therapy on beta-cell function

Short-term treatment with ALO/PIO or ALO improved glycemic control in well-controlled T2DM patients, but only combined ALO/PIO improved beta-cell function. These data support that initial combination therapy with a DPP-4 inhibitor and TZD to address multiple core defects in T2DM may be a sensible approach (European Journal of Endocrinology)